Literature DB >> 7002419

Drug kinetics in burn patients.

R J Sawchuk, T S Rector.   

Abstract

Thermal trauma reportedly induces a spectrum of intricate physiological alterations that often involve cardiovascular, hepatic, renal, and dermatological functions. Individual responses to varying degrees of burn and secondary complications may produce unpredictable changes in the pharmacokinetics of drugs. A number of reports describing the disposition of aminoglycoside antibiotics in burn patients have demonstrated clinially significant alterations in the pharmacokinetics of this class of drugs. Several authors have found significantly reduced serum half-lives in burn patients as compared with average values in non-burned subjects. Increased aminoglycoside clearances in some burn patients have been attributed to increased glomerular filtration secondary to elevated cardiac output, prostaglandin formation, and glucagon secretion: others attribute this to enhanced elimination of drug across damaged skin tissue. Monitoring of serum aminoglycoside concentrations is recommended because of the low therapeutic index of these agents and the variable course of renal function following burn injury. Topical application of mafenide acetate, providone iodine, and gentamicin to burn wounds has resulted in varying amounts of systemic absorption. Various systemic toxicities have been attributed to these topical therapies, especially in patients with compromised renal function. The extent and area of the burn, degree of hydration, and the amount of drug applied are factors influencing transcutaneous absorption. Sulphonamide derivatives are excreted in the urine subsequent to the application of silver sulphadiazine cream, but silver ions appear to be localised on surface tissue and are thus unavailable to the subeschar space. Additional studies are needed to characterise the pharmacokinetics of medications commonly administered to burn patients. Unfortunately, the marked variability and fluctuations in pathophysiological status following burn trauma often confound the interpretation of such kinetic investigations.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7002419     DOI: 10.2165/00003088-198005060-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  6 in total

Review 1.  Pharmacokinetics of drugs in cystic fibrosis.

Authors:  M Spino
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 2.  Pathophysiology and pharmacokinetics following burn injury.

Authors:  P L Bonate
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

4.  Vancomycin pharmacokinetics in burn patients and intravenous drug abusers.

Authors:  M J Rybak; L M Albrecht; J R Berman; L H Warbasse; C K Svensson
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics in patients with burns.

Authors:  U Jaehde; F Sörgel
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

Review 6.  Clinical pharmacological and therapeutic considerations in general intensive care. A review.

Authors:  M L Farina; M Bonati; G Iapichino; A Pesenti; F Procaccio; L Boselli; M Langer; A Graziina; G Tognoni
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.